Clinical and pharmacokinetic study of sunitinib and docetaxel in women with advanced breast cancer

Sunitinib plus docetaxel on Schedule 2/1 did not result in any clinically significant drug-drug interactions. This combination was manageable and exhibited antitumor activity.